Catalent wraps up San Diego site buildout as it continues to make waves with global acquisitions – Endpoints News

[ad_1]

For the past 20 years, Novartis and Roche have been more than just metropolitan rivals ruling towering pharmaceutical dynasties. Novartis also holds a significant proportion of Roche shares, which equates to almost a third of the voting rights.

Roche is now buying back this stake for US $ 20.7 billion.

“After more than 20 years as a Roche shareholder, we have decided that now is the right time to monetize our investment,” said Vas Narasimhan, CEO of Novartis, adding that the cash will be used for purposes in line can be used with the current capital allocation.

Read More

Unlock this story right away and join the 121,700+ biopharma professionals who read endpoints every day – and it’s free.

REGISTER LOG IN

[ad_2]

Source link